We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
51
Sutro Biopharma
STRO
$401M
$4.99M 0.46%
43,789
+3,000
+7% +$312K
SBBP
52
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.74M 0.43%
951,600
+20,000
+2% +$98.5K
MHK icon
53
Mohawk Industries
MHK
$7.5B
$4.67M 0.43%
37,000
+26,339
+247% +$3.43M
QURE icon
54
uniQure
QURE
$3.03B
$4.61M 0.42%
77,349
-155,500
-67% -$6.95M
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
$4.59M 0.42%
+345,535
New +$3.67M
MLNX
56
PUT
DELISTED
Mellanox Technologies, Ltd.
MLNX
$4.56M 0.42%
+38,500
New +$3.87M
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.53M 0.41%
88,015
-45,000
-34% -$1.94M
SEDG icon
58
SolarEdge
SEDG
$2.51B
$4.49M 0.41%
+119,067
New +$4.76M
QTTB icon
59
Q32 Bio
QTTB
$466M
$4.46M 0.41%
8,944
– –
GBT
60
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.23M 0.39%
80,000
-67,000
-46% -$3.29M
MGNX icon
61
MacroGenics
MGNX
$235M
$4.22M 0.39%
+235,000
New +$4.06M
ARGX icon
62
argenx
ARGX
$53.4B
$4.19M 0.38%
33,581
-53,500
-61% -$6.29M
XHB icon
63
State Street SPDR S&P Homebuilders ETF
XHB
$1.6B
$4.16M 0.38%
+107,934
New +$4M
LOGC
64
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$4.13M 0.38%
417,625
– –
DTIL icon
65
Precision BioSciences
DTIL
$180M
$4.04M 0.37%
+7,500
New +$3.98M
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.93M 0.36%
1,490,000
– –
NICE icon
67
Nice
NICE
$5.79B
$3.89M 0.36%
+31,771
New +$3.58M
CBIO
68
Crescent Biopharma
CBIO
$537M
$3.88M 0.35%
3,110
+600
+24% +$687K
TLT icon
69
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
$3.79M 0.35%
+30,000
New +$3.65M
ITCI
70
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.65M 0.33%
+300,000
New +$3.83M
FISV
71
Fiserv Inc
FISV
$28.8B
$3.56M 0.33%
+40,365
New +$3.33M
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.54M 0.32%
19,779
-17,221
-47% -$2.59M
FSCT
73
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$3.17M 0.29%
75,625
+16,456
+28% +$590K
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.13M 0.29%
+33,080
New +$4.35M
RVLP
75
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$3.11M 0.28%
864,006
-58,194
-6% -$428K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.